Marshall Wace
BDTX icon

Marshall Wace’s Black Diamond Therapeutics BDTX Stock Holding History

Marshall Wace’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Buy
896,602
+60,336
+7% +$148K ﹤0.01% 1953
2026
Q1 		$1.78M Sell
836,266
-273,822
-25% -$651K ﹤0.01% 1849
2025
Q4 		$2.7M Sell
1,110,088
-189,120
-15% -$670K ﹤0.01% 1433
2025
Q3 		$4.92M Buy
1,299,208
+561,333
+76% +$1.64M 0.01% 1182
2025
Q2 		$1.83M Buy
+737,875
New +$1.42M ﹤0.01% 1598
2024
Q4 		– Sell
-97,166
Closed -$423K – 2585
2024
Q3 		$423K Buy
97,166
+2,629
+3% +$14.3K ﹤0.01% 1980
2024
Q2 		$441K Buy
+94,537
New +$507K ﹤0.01% 2007
2024
Q1 		– Sell
-22,924
Closed -$64.4K – 2435
2023
Q4 		$64.4K Buy
+22,924
New +$53.8K ﹤0.01% 2065
2021
Q2 		– Sell
-140,232
Closed -$3.4M – 2654
2021
Q1 		$3.4M Buy
140,232
+97,151
+226% +$2.62M 0.02% 1045
2020
Q4 		$1.38M Buy
+43,081
New +$1.42M 0.01% 1082
2020
Q3 		– Sell
-8,007
Closed -$338K – 1577
2020
Q2 		$338K Sell
8,007
-20,783
-72% -$765K ﹤0.01% 1301
2020
Q1 		$718K Buy
+28,790
New +$876K 0.01% 889

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Marshall Wace's BDTX Position: Q2 2026 in Review

Marshall Wace increased its Black Diamond Therapeutics (BDTX) stake by 7.2% in Q2 2026, buying an estimated $148K and bringing the position to 896,602 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Marshall Wace first reported a position in BDTX in Q1 2020 and has held it in 12 quarters since. The position peaked at $4.92M in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Marshall Wace held 896,602 shares of Black Diamond Therapeutics worth $1.66M as of Q2 2026.
  • Marshall Wace bought 60,336 Black Diamond Therapeutics shares in Q2 2026, an estimated $148K.
  • Black Diamond Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1953 holding.
  • Marshall Wace first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 12 quarters since.
  • Marshall Wace's Black Diamond Therapeutics position peaked at $4.92M in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.